| Literature DB >> 23264063 |
Jamie Wikenheiser1, Ganga Karunamuni, Eddie Sloter, Mary K Walker, Debashish Roy, David L Wilson, Michiko Watanabe.
Abstract
Differential tissue hypoxia drives normal cardiogenic events including coronary vessel development. This requirement renders cardiogenic processes potentially susceptible to teratogens that activate a transcriptional pathway that intersects with the hypoxia-inducible factor (HIF-1) pathway. The potent toxin 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is known to cause cardiovascular defects by way of reduced myocardial hypoxia, inhibition of angiogenic stimuli, and alterations in responsiveness of endothelial cells to those stimuli. Our working hypothesis is that HIF-1 levels and thus HIF-1 signaling in the developing myocardium will be reduced by TCDD treatment in vivo during a critical stage and in particularly sensitive sites during heart morphogenesis. This inadequate HIF-1 signaling will subsequently result in outflow tract (OFT) and coronary vasculature defects. Our current data using the chicken embryo model showed a marked decrease in the intensity of immunostaining for HIF-1α nuclear expression in the OFT myocardium of TCDD-treated embryos. This area at the base of the OFT is particularly hypoxic during normal development; where endothelial cells initially form a concentrated anastomosing network known as the peritruncal ring; and where the left and right coronary arteries eventually connect to the aortic lumen. Consistent with this finding, anomalies of the proximal coronaries were detected after TCDD treatment and HIF-1α protein levels decreased in a TCDD dose-dependent manner.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23264063 PMCID: PMC3632717 DOI: 10.1007/s12012-012-9194-7
Source DB: PubMed Journal: Cardiovasc Toxicol ISSN: 1530-7905 Impact factor: 3.231
Fig. 1Proposed intersection of the toxin and hypoxic pathway. Both pathways require HIF-1β/ARNT
Fig. 2HIF-1α staining of control verses TCDD-treated embryos. Specific sites of immunofluorescent staining for HIF-1α near the OFT myocardium of a stage 30 chicken embryonic heart. HIF-1α nuclear-localized immunostaining intensity and frequency was high in the control (a–c) OFT myocardium (arrows in b, c) while lower in the TCDD-treated embryos (f–h). However, TCDD-treated embryos had increased HIF-1α staining within the endocardial cushions (g between arrows, h). My myocardium and EC endocardial cushions. Bright staining in d and h is autofluorescence of red blood cells and not that of nuclear-localized HIF-1α staining
Fig. 3HIF-1α and Tie2 protein expression after TCDD exposure. Protein expression as qualitatively assessed by Western blot decreased for both HIF-1α and Tie2 after exposure to 1.0 pmol and 3.0 pmol of TCDD. Decreases in HIF-1α were dose-dependent and were not statistically significant until embryos were exposed to 3.0 pmol of TCDD
Fig. 4Anatomy of the proximal coronaries after TCDD exposure. Cryosections of hearts were immunostained with anti-smooth muscle actin to identify coronary arteries. The pattern of the proximal coronary arteries changed and septal defects were seen after a 3.0-pmol exposure to TCDD. Coronary arteries and OFT septal defects were observed in 1 of 7 embryos after a 1.0-pmol exposure to TCDD (data not shown). After treatment with 3.0 pmol of TCDD, 5 of 8 embryos displayed coronary artery anomalies. The anomalies included retro-aortic coronary (a, f), double right coronary (b, g), or an incomplete lumen (c). 4 of 8 embryos displayed septal defects (arrows in d) after exposure to 3.0 pmol TCDD. Diagrams of the proximal attachments of the left and right coronary arteries in a stage 35 (ED 9) embryo were deduced from the observation of serial transverse sections (e–g). Asterisks in c and g represent a sinus or ampulla near the attachment of the right coronary artery to the aorta. A Anterior, P posterior, L left, R right, Ao aorta, Pt pulmonary trunk, LC left coronary, RC right coronary, RAD right anterior descending—present in the chicken
A Summary of dosage and mortality rates. B Summary of septal and coronary artery anomalies
| Treatment | Injected | Collected | Dead | Description |
|---|---|---|---|---|
|
| ||||
| Vehicle | 12 | 10 (83 %) | 2 (17 %) | Normal |
| 1.0 pmol of TCDD/g | 12 | 7 (58 %) | 5 (42 %) | Similar to controls |
| 3.0 pmol of TCDD/g | 15 | 8 (53 %) | 7 (47 %) | Hemorrhaging and body cavities failed to close |